Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Rinvoq on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Rinvoq (upadacitinib) is a Janus kinase (JAK) inhibitor approved by the FDA for multiple conditions, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, ulcerative colitis, Crohn's disease, and polyarticular juvenile idiopathic arthritis, generally in patients with an inadequate response or intolerance to one or more TNF blockers.
Rinvoq selectively inhibits JAK1, a signaling protein involved in the inflammatory pathways underlying these autoimmune and inflammatory conditions. By blocking JAK1 signaling, Rinvoq helps reduce inflammation and disease activity across its approved indications.
Rinvoq is used across a wide range of immune-mediated inflammatory conditions in adults, and in certain pediatric populations for juvenile idiopathic arthritis, typically after standard therapies including TNF blockers have not provided adequate control.
For rheumatoid arthritis, the typical dose is 15 mg orally once daily as an extended-release tablet. Dosing varies by indication, and a treating physician determines the appropriate dose and formulation (tablet or oral solution) for each patient.
Boxed Warning — Rinvoq: Serious infections, mortality, malignancy, major adverse cardiovascular events (MACE), and thrombosis have been observed with JAK inhibitors, including Rinvoq. Patients treated with JAK inhibitors are at increased risk of serious bacterial, fungal, viral, and opportunistic infections, including tuberculosis, that may lead to hospitalization or death. A higher rate of all-cause mortality, including sudden cardiovascular death, has been observed with another JAK inhibitor compared to TNF blockers. Malignancies, including lymphoma, have occurred, along with a higher rate of MACE and thrombosis, based on a large safety trial in rheumatoid arthritis patients 50 years and older with cardiovascular risk factors.
Patients should be evaluated for tuberculosis before starting treatment and monitored for signs of infection throughout therapy. Rinvoq should be avoided in patients with active serious infections.
Patients 50 years and older with at least one cardiovascular risk factor should be evaluated carefully, as this population showed elevated risk in safety trials.
Complete blood counts, liver enzymes, and lipid levels should be monitored periodically during treatment.
Rinvoq may cause fetal harm. Effective contraception should be used during treatment.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Rinvoq is manufactured and marketed by AbbVie Inc. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating rheumatologist, dermatologist, or gastroenterologist confirming diagnosis and prior treatment history, depending on the indication. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy across multiple inflammatory and autoimmune conditions, Rinvoq is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Rinvoq directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Rinvoq should be stored between 2°C and 25°C, in its original bottle to protect from moisture, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Rinvoq through NPP's regulated import pathway, with rheumatology, dermatology, and gastroenterology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support rheumatology and immunology care coordination and documentation for Rinvoq access.
Delhi's major hospitals assist patients with prescription support and documentation for Rinvoq.
Bangalore's specialist network offers access coordination for eligible patients seeking Rinvoq.
Chennai-based rheumatology specialists coordinate Rinvoq access alongside comprehensive inflammatory disease care.
Hyderabad's care institutions support patients pursuing Rinvoq therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Rinvoq.
Pune-based specialists assist with prescription support and Rinvoq treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Rinvoq.
Kochi's specialist units assist patients with the documentation needed for Rinvoq access.
Chandigarh's care centers support Rinvoq treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Rinvoq access process.
Lucknow-based centers assist patients pursuing Rinvoq therapy.
Bhubaneswar's institutions support access to Rinvoq for eligible patients.
Guwahati's specialists help coordinate Rinvoq access for patients across the Northeast.
Patients in other cities across India can also access Rinvoq through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
